Table 3.
Selected published GFR results from dogs with naturally-occurring or clinically relevant induced diseases
| Disease condition | Marker | Number of dogs | Method | GFR resultsa | Reference |
|---|---|---|---|---|---|
| Cardiac disease | |||||
| Chronic valvular disease (NYHA class I–II) | exogenous creatinine | 15 | CLplasma | 3.1 (0.8) | Nicolle et al., 2007 |
| Chronic valvular disease (NYHA class III–IV) | exogenous creatinine | 9 | CLplasma | 1.7 (0.7) | Nicolle et al., 2007 |
| Chronic valvular disease, non-azotemic | exogenous creatinine | 16 | CLplasma | 3.2 (0.6) | Nicolle et al., 2007 |
| Chronic valvular disease, azotemic | exogenous creatinine | 8 | CLplasma | 1.4 (0.5) | Nicolle et al., 2007 |
| Infectious disease | |||||
| Leishmaniasis, secondary IRIS CKD stage 1, non-proteinuric | exogenous creatinine | 8 | CLplasma | 4.4 (0.74) | Cortadellas et al., 2008 |
| Leishmaniasis, secondary IRIS CKD stage 1, proteinuric | exogenous creatinine | 10 | CLplasma | 4.5 (1.44) | Cortadellas et al., 2008 |
| Leishmaniasis, secondary IRIS CKD stage 2 | exogenous creatinine | 5 | CLplasma | 2.8 (0.97) | Cortadellas et al., 2008 |
| Leishmaniasis, secondary IRIS CKD stage 3 | exogenous creatinine | 3 | CLplasma | 1.5 (0.43) | Cortadellas et al., 2008 |
| Renal disease | |||||
| 1 month following serial unilateral renal biopsies of normal kidneys | 99mTc-DTPA | 10 | Renal scintigraphy | 3.37 | Groman et al., 2004 |
| Endocrine disease | |||||
| Hypothyroidism (I131-induced) | exogenous creatinine | 8 | CLplasma | 2.13 (0.48) | Panciera and Lefebvre, 2009 |
| Hypothyroid (naturally-occurring) | exogenous creatinine | 14 | CLplasma | 1.6 (0.4) | Gommeren et al., 2009 |
| Post 1 month thyroxine therapy | exogenous creatinine | 14 | CLplasma | 2.1 (0.4) | Gommeren et al., 2009 |
| Post 6 month thyroxine therapy | exogenous creatinine | 11 | CLplasma | 2.0 (0.4) | Gommeren et al., 2009 |
| Drug effects in healthy dogs | |||||
| Post-anesthesia and tramadol analgesia | Iohexol | 8 | CLplasma | 4.56 ± 0.18 | Kongara et al., 2009 |
| Post-anesthesia and parecoxib analgesia | Iohexol | 8 | CLplasma | 4.56 ± 0.23 | Kongara et al., 2009 |
| Post-anesthesia and tramadol, parecoxib, and pindolol analgesia | Iohexol | 8 | CLplasma | 4.62 ± 0.22 | Kongara et al., 2009 |
| Post-anesthesia and morphine analgesia | Iohexol | 8 | CLplasma | 4.54 ± 0.25 | Kongara et al., 2009 |
| Post-anesthesia, no analgesia | Iohexol | 8 | CLplasma | 4.69 ± 0.75 | Kongara et al., 2009 |
| During xylazine, ketamine, and halothane anesthesia | 99mTc-DTPA | 10 | Renal scintigraphy | 4.6 ± 0.32 | Fusellier et al., 2007 |
| During propofol anesthesia | 99mTc-DTPA | 10 | Renal scintigraphy | 3.78 ± 0.37 | Fusellier et al., 2007 |
| Following 30 days of low-dose ketoprofen | exogenous creatinine | 7 | CLplasma | 5.11 (0.72) | Narita et al., 2006 |
NYHA, New York Heart Association; IRIS, International Renal Interest Society; CKD, chronic kidney disease; CLplasma, plasma clearance
a
Results reported as mL/min/kg, mean (standard deviation) or mean ± standard error of the mean